Trial Profile
First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AV 0113 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms GBM-Vax
- Sponsors Activartis Biotech
- 17 Oct 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database.
- 30 May 2014 Interim results on overall survival presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2013 Interim results presented at the 104th Annual Meeting of the American Association for Cancer Research.